Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) i...(and Itnogen) is marketed across Europe b...),Health

Date:8/26/2009

and Itnogen) is marketed across Europe by ProStrakan's own, in-house sales forces and is out-licensed by ProStrakan to Bayer Schering Pharma (BSP) in 147 countries, in many of which FORTESTA is planned to be promoted alongside Nebido((R)), which is Endo Pharmaceuticals' testosterone undecanoate product, or long-acting injectable, currently under regulatory review with the FDA in the United States.

About Hypogonadism

Hypogonadism, or low testosterone, is a common yet largely under-recognized and under-treated condition. An estimated 13.8 million American men have testosterone levels characterized as below normal (testosterone <300ng/dl). Yet despite this high prevalence, only about 9 percent of men with low testosterone are treated with testosterone replacement therapy.

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels, Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the U.K., U.S., France, Germany, Spain and other EU countries. www.prostrakan.com

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM((R)), a topical patc
'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
2. Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals
3. Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
4. Raptor Pharmaceuticals Raises $5 Million
5. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
6. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
7. NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
8. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
9. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
10. Sound Pharmaceuticals Receives an Office of Naval Research Award for Its Hearing Loss Research and Development
11. Adamas Pharmaceuticals Raises $40 Million in Series D Financing